Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Healthcare | Small Cap
Health Score : 8.79Dr Lal Pathlabs Ltd. demonstrates exceptional financial health, characterized by outstanding profitability and robust growth. The company is highly effective at turning revenue into profit and is expanding its earnings and sales at an impressive rate. Its financial foundation is remarkably strong, with very low reliance on debt, which minimizes financial risk. The company also maintains a very strong capacity to cover its immediate financial obligations. A key area of mixed performance is in its operational efficiency; while it manages its inventory and customer payments very effectively, it is not generating as much sales from its long-term assets as it could be. There is also a potential concern regarding the sustainability of its dividend payments, as earnings do not appear to fully cover them. Overall, the company's strong profitability and growth paint a positive picture, supported by a secure financial structure.
Health Score : 8.79Dr Lal Pathlabs Ltd. demonstrates exceptional financial health, characterized by outstanding profitability and robust growth. The company is highly effective at turning revenue into profit and is expanding its earnings and sales at an impressive rate. Its financial foundation is remarkably strong, with very low reliance on debt, which minimizes financial risk. The company also maintains a very strong capacity to cover its immediate financial obligations. A key area of mixed performance is in its operational efficiency; while it manages its inventory and customer payments very effectively, it is not generating as much sales from its long-term assets as it could be. There is also a potential concern regarding the sustainability of its dividend payments, as earnings do not appear to fully cover them. Overall, the company's strong profitability and growth paint a positive picture, supported by a secure financial structure.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
62.81
Industry Median
32.53
Small Cap Median
32.53
P/E RATIO
63.21
P/B RATIO
12.70
Industry Median
3.84
Small Cap Median
3.84
P/S RATIO
11.58
Industry Median
3.46
Small Cap Median
3.46
Others
PEG RATIO
5.02
EV/EBITDA RATIO
36.63
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹1904.4 as on Sep 1, 2026.
Growth Score : 10.00The company is experiencing a period of outstanding growth across all major financial dimensions. Revenues, profits, and earnings per share are all expanding at an excellent rate. This comprehensive growth indicates strong market demand for its services, successful business strategies, and effective management. The expansion of its asset base suggests continued investment to support future growth. This strong upward trajectory is a very positive sign for the company's future prospects and its ability to create value for shareholders.
Revenue Growth RateAverageOperating Profit Growth RateAverage
Earnings Per Share (EPS) GrowthGoodAsset Growth RateAverageNet Income Growth RateAverage| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 32.01 | -3.35 | 10.41 | 10.51 | 12.27 |
| Operating Profit Growth Rate | 28.67 | -12.66 | 24.29 | 14.61 | 12.03 |
| Earnings Per Share (EPS) Growth | 18.3 | -30.74 | 49.48 | 36.04 | 3.4 |
| Asset Growth Rate | 41.06 | 1.71 | 2.98 | 10.55 | 15.96 |
| Net Income Growth Rate | 18.24 | -31.14 | 50.21 | 35.91 | 3.66 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Dr Lal Pathlabs Ltd | 8.79 | 63.21 | Highly Overvalued | 782.00 | 30.32 | 510.00 |
| 2 | Vijaya Diagnostic Centre Ltd | 8.44 | 89.17 | Neutral | 337.00 | 17.33 | 173.00 |
| 3 | Indegene Ltd | 7.58 | 36.36 | Overvalued | 619.00 | 8.80 | 401.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
Quarterly Report⬤30th Apr 26
Consolidated Financial Results (Unaudited/Audited) for the Quarter and Year Ended March 31, 2026
UNDEFINED SENTIMENT
Concall Report⬤3rd Feb 26
Q3 FY26 Earnings Conference Call Transcript
NEUTRAL SENTIMENT
Concall Report⬤31st Oct 25
Q2 H1 FY26 Earnings Conference Call Transcript
NEUTRAL SENTIMENT
Dr Lal Pathlabs Ltd. is a leading diagnostic and related healthcare service provider in India. It offers a comprehensive range of pathology and radiology tests, serving individual patients, hospitals, and other healthcare providers. The company operates an extensive network of labs and patient service centers, maintaining a strong market position in the Indian diagnostics industry.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Dr Lal Pathlabs Ltd's P/E ratio (TTM) is 62.81, compared to the industry median of 32.53 and large cap median of 32.53.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Dr Lal Pathlabs Ltd's P/B ratio is 12.70, compared to the industry median of 3.84 and large cap median of 3.84.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Dr Lal Pathlabs Ltd's P/S ratio is 11.58, compared to the industry median of 3.46 and large cap median of 3.46.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Dr Lal Pathlabs Ltd's PEG ratio is 5.02.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Dr Lal Pathlabs Ltd's EV/EBITDA ratio is 36.63.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Dr Lal Pathlabs Ltd's ROE is 20.33%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Dr Lal Pathlabs Ltd's ROA is 24.86%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Dr Lal Pathlabs Ltd's ROCE is 28%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Dr Lal Pathlabs Ltd's operating margin is 28.30%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Dr Lal Pathlabs Ltd's net margin is 18.46%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Dr Lal Pathlabs Ltd's current ratio is 3.33.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Dr Lal Pathlabs Ltd's debt-to-equity ratio is 0.08.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Dr Lal Pathlabs Ltd's interest coverage ratio is 30.09.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Dr Lal Pathlabs Ltd's DPS is ₹24.41.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Dr Lal Pathlabs Ltd's EPS is 3.40.
(Source line: "Ratios as of 05 Nov 2026, based on last traded price of ₹1904.40. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1949
Headquarters: New Delhi, Delhi
Core Offerings: Pathology tests, Radiology tests, Diagnostic services, Health check-up packages, Corporate client services
Stock Listing: NSE (LALPATHLAB), BSE (539524)
Promoter: Dr. Arvind Lal / Lal family
Founded in 1949 by Dr. S.K. Lal in Delhi, Dr Lal Pathlabs began as a small pathology lab. Dr. Arvind Lal, a renowned pathologist, took charge in 1977 and spearheaded its expansion. The company established its National Reference Laboratory in Delhi, expanding its network across India. It successfully completed its Initial Public Offering (IPO) in 2015, becoming a publicly listed entity. Today, it stands as one of India's largest and most reputed diagnostic chains.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Diagnostic and Related Healthcare Services | ~100% | N/A (Represents overall company EBITDA) |
Diagnostic and Related Healthcare Services: This primary segment encompasses a vast array of pathology and radiology tests, including routine and specialized blood tests, advanced molecular diagnostics, genetic testing, microbiology, and imaging services like X-rays and ultrasounds.
The company operates through a highly integrated hub-and-spoke model, featuring a National Reference Laboratory, regional reference labs, and numerous patient service centers and collection points spread across India.
Services are delivered to individual patients directly, as well as through partnerships with hospitals, corporate clients, and other healthcare institutions, emphasizing quality, speed, and accuracy.
Dr. Arvind Lal (Chairman & Managing Director): A highly respected pathologist and entrepreneur, Dr. Lal has been instrumental in transforming the company into a national leader in diagnostic services. He holds an MD in Pathology. Dr. Vandana Lal (Whole-time Director & Chief Operating Officer): A qualified pathologist, Dr. Vandana Lal oversees the company's day-to-day operations and plays a critical role in maintaining high standards of quality and service delivery.
Pathlabs Diagnostics Private Limited
Dr. Lal Pathlabs Nepal Private Limited
A-Path Referrals Private Limited
CVD Clinical Research Private Limited
A 1:1 bonus issue was undertaken in FY2018. No other major recent corporate actions (such as rights issues or significant M&A) on record.
The Dr Lal Pathlabs Ltd share price today is ₹1904.40 on NSE (LALPATHLAB), as of 05 Nov 2026.
As of 05 Nov 2026, Dr Lal Pathlabs Ltd share price is ₹1904.40, with previous close ₹1904.40. Today's range is ₹1904.40 to ₹1904.40. The 52-week range is ₹1272.60 to ₹2049.
As of today, Dr Lal Pathlabs Ltd's market cap is ₹31,993.92 crore (Large Cap).
Dr Lal Pathlabs Ltd's current P/E ratio is 62.81, compared to the DIVERSIFIED CONSUMER SERVICES sector average of 50.
Dr Lal Pathlabs Ltd's current P/B ratio is 12.70.
Dr Lal Pathlabs Ltd's current dividend yield is 1.28%. Last dividend of ₹6.00 per share was declared on 26-Jul-2024.
Dr Lal Pathlabs Ltd's EPS (TTM) is ₹3.40.
Dr Lal Pathlabs Ltd. is a leading diagnostic and related healthcare service provider in India. It offers a comprehensive range of pathology and radiology tests, serving individual patients, hospitals, and other healthcare providers. The company operates an extensive network of labs and patient service centers, maintaining a strong market position in the Indian diagnostics industry.
Dr Lal Pathlabs Ltd is promoted by Dr. Arvind Lal / Lal family, holding 53.21% as of 05 Nov 2026.
Dr Lal Pathlabs Ltd is listed on NSE (LALPATHLAB) and BSE (539524). Its next quarterly results are expected on August 2024 (Q1 FY25).
Adjusted Earnings Per Share (Adjusted EPS)